key: cord-1039579-76tq84ss
authors: Zarei, Mohammad; Bose, Deepanwita; Nouri‐Vaskeh, Masoud; Tajiknia, Vida; Zand, Ramin; Ghasemi, Mehdi
title: Long‐term side effects and lingering symptoms post COVID‐19 recovery
date: 2021-09-09
journal: Rev Med Virol
DOI: 10.1002/rmv.2289
sha: 26ceeb917ad62a8906a4ce93f0ea04140d2c269a
doc_id: 1039579
cord_uid: 76tq84ss

Since the Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), our understanding regarding the pathophysiology and clinical manifestations of this disease have been improving. However, we still have limited data on long‐term effects and lingering symptoms of post COVID‐19 recovery. Despite predilection of COVID‐19 for lungs, multiple extra‐pulmonary manifestations appear in multiple organs and biological systems and with continued infection and recovery worldwide. It is necessary that clinicians provide patients with previous SARS‐CoV‐2 infection with expectations of long‐term effects during or after recovery from COVID‐19. Herein, we review the long‐term impact of COVID‐19 on different organ systems reported from different clinical studies. Understanding risk factors and signs and symptoms of long‐term consequences after recovery from COVID‐19 will allow for proper follow‐up and management of the disease post recovery.

This review will detail each COVID-19 affected organ and analyse the effects on it post-COVID-19 recovery with a major focus on long-term effects that patients might experience.

1.1.1 | Long-term effects on the pulmonary system during the path to recovery ACE2 receptor is expressed in bronchial epithelium and type II pneumocytes. These cells are the major alveolar surfactant producer with immunoregulatory functions besides their function as stem cell progenitors of type I pneumocytes. The most clinically manifested complication is acute hypoxaemia, requiring ventilators. 3 The comparison to non-intensive care unit (ICU) and ICU admitted patients had higher levels of interleukin (IL-7), IL-10, GCSF, IP10 (CXCL10), MCP1 (CCL2), MIP1A (CCL3) and tumor necrosis factor (TNF)-α. 3 A recent retrospective study on 57 patients, the impact of COVID-19 on pulmonary function in the early convalescence phase was investigated. 4 It collected the data 30 days after discharge and they reported that 54.3% had abnormal CT findings and 75.4% had an abnormal pulmonary function. Compared to the non-severe cases, severe infection cases showed diffusing capacity of the lung for carbon monoxide (DLCO) impairment (75.6% vs. 42.5%). They reported that in more than half of the COVID-19 patients there was an impaired diffusion capacity, lower muscle strength and lung imaging abnormalities. 4 A 3-month post-discharge study on critical COVID-19 patients who were admitted to ICU showed 55% of patients had impaired lung function, exhibiting restrictive patterns, altered DLCO, 65% of patients reported 6 min walking distance (6MWD) below 80%. The study also reported obstructive sleep apnoea as a predictor of fibrosis on a 3-month chest computed tomography (CT) scan. 5 Weerahandi et al. 6 studied a post-discharge health status and symptoms in patients with severe COVID-19, their study was conducted 30-40 days post-discharge on 152 participants. About 74% of participants reported shortness of breath. Physical and mental health deterioration was also reported in the post-COVID-19 participants.

In a study done on 55 COVID-19 survivors 3 months after recovery, it was reported that there were radiological (ground-glass opacity [GGO], consolidation and interstitial thickening) and physiological abnormalities in 70% of the patients. The measurements of Ddimers can be a potential marker for the prediction of impaired diffusion defect. 7 Lung pathologies in 63% of patients were confirmed by CT scans, the majority of the patients had bilateral GGO and reticulation in the lower lung lobes. The study also concluded significant improvements in symptoms and cardiopulmonary conditions over time. 8 Most recent reviews address that the pulmonary fibrosis 9,10 is the novel sequelae of the current pandemic and a follow-up treatment to be considered for pulmonary long COVID. 11 1.1.2 | Long-term effects on the cardiovascular system during the path to recovery Vascular injury or myocardial injury can occur by a direct viral infection and/or indirectly from immune responses to viral infection.

Acute clinical cardiovascular manifestations among hospitalised patients with COVID-19 are ventricular dysfunction, cardiogenic shock, myocardial ischaemia/infarction, acute heart failure, cardiac shock, stress cardiomyopathy, arrhythmias, venous thromboembolism and arterial thrombosis. 12 Indirect myocardial injury corresponds to the hypoxia-induced due to hypoxic respiratory failure causing small vessel ischaemia microvascular injury and thrombosis.

Cardiac injury can be also caused due to the dysfunctional immune response reviewed in detail by Chung et al. 13 The study by Lindner et al. evaluated the presence of SARS-CoV-2 in the myocardial tissues of 39 autopsy cases. SARS-CoV-2 was found in 24 of 39 patients, with a viral load above 1000 copies per microgram RNA in 16 patients. The expression of proinflammatory genes was increased in the 16 patients with high viral load. 14 In a German cohort of 100 COVID-19 recovered patients, 78 patients were detected with cardiac involvement, of which 60 had myocardial inflammation. They report that the recently recovered patients had lower left ventricular ejection fraction, higher left ventricular volumes, higher left ventricular mass and raised levels of T1 and T2. Highly sensitive troponin T was also detected (3 pg/mL or greater) in 71 patients which was significantly elevated in 5 patients (13.9 pg/mL). COVID-19 has evidence of Troponin being elevated which is an indicator of cardiac damage. Lymphatic inflammation was revealed by the endomyocardial biopsies from patients with the most abnormal cardiovascular magnetic resonance (CMR). The overall findings suggested that 25% have evidence of ongoing myocardial inflammation 3 months after diagnosis. 15 Huang et al. 16 22 In these studies, a sizable percentage did not recover to baseline serum creatinine at discharge it brings the importance of management and monitoring patients post-AKI to reduce any reoccurrence and mitigate long-term adverse consequences. Stockman et al. 23 followed 74 hospitalised patients and found a high rate of long-term recovery in survivors of COVID-19-associated AKI requiring kidney replacement therapy. Whilst another study with 115 ICU patients requiring AKI renal replacement therapy. By the end of follow-up, 51% of patients died whilst 41% had recovery. Stevens et al. 24 concluded that a high rate of renal recovery survivors of COVID-19 is associated with AKI requiring replacement therapy. Recent reviews described in detail the viral neuropathy 31 and pathophysiology of COVID-19 associated AKI. 32, 35 Study conducted by Prevention of Progressive Renal Insufficiency (PIRP) project, concluded that COVID-19 infection and mortality in chronic non dialysis patients were higher than the general population. 33 Another study on patients with end stage kidney disease (ESKD) shows that death was 17% higher among patients with dialysis and 30% higher with patients with kidney transplant. 34 1.1.4 | Long-term effects on the liver during the path to recovery Elevated liver function tests have been reported with abnormal levels of aspartate aminotransferases (AST) and alanine aminotransferase (ALT). 36 Liver injury can also be related to drugs. Most patients with COVID-19 show mild liver damage and return to normal, targetted hepatoprotective therapy is necessary in patients with severe liver injury. 37 Zhan et al. followed 192 SARS-CoV-2 hospitalised patients. Liver injury was detected in 39% at admission and 69.2% had a liver injury during hospitalisation. In case of severe COVID-19 hospitalisations, liver injury was observed in 86% of patients. 38 An et al. 25 The level of total protein, albumin, albumin to globulin ratio (A/G) and AST/ ALT in patients were significantly lower than the control group. And the levels of ALT, gammaglutamyl transferase and alkaline phosphatase levels were significantly higher. About 46 patients did the serologic tests at 40 days after discharge,

COVID-19 was not just age bias but also sex bias towards severe disease. 41 A meta-analysis on more than 3 million reported global cases conformed that male COVID-19 infected patients had 3 times the odds of requiring the intensive treatment unit admission and higher odds of death compared to women. 42 In a recent in vitro study, it was shown that 17β-estradiol can reduce SARS-CoV-2 infection, the group also showed that TMPRSS2 gene expression can be reduced by estrogen after SARS-Cov-2 infection, TMPRSS2 is involved in COVID-19 infectiveness capacity. 43 In a meta-data study with 68,466 global cases, it was observed that there was a higher fatalities rate in males compared to agedmatched females. They also observed that premenopausal women are disproportionately more infected than men, but they do not become seriously ill as shown with a low fatality rate. 44 A randomised interventional clinical trial with 110 participants is The trial hypothesises that a short 7-day transdermal patch applied to the infected patients will be safe and reduce severe symptoms in men and older women, the patients will be followed for a time course and disease outcome.

A study by Li Testosterone, follicle-stimulating hormone and luteinising hormone levels were normal in patients recovered from COVID-19 27 Endocrine system Retrospective study of thyroid function analysis with 50 COVID-19 infected patients has been done in comparison to healthy control.

The severity of the COVID-19 infection lowers the thyroid hormone and thyroid-stimulating hormone (TSH) and total triiodothyronine levels. A 53% of the patients had lower TSH. After recovery: thyroid hormones and thyroid function was similar to healthy controls 28 Neurological systems

Retrospective cohort study had 236,379 COVID-19 survivors: 6-months neurological and psychiatric outcome A 33.62% had a neurological or psychiatric diagnosis. The patients requiring intensive therapy unit treatment, the neurological or psychiatric diagnosis was 46.2%. 29 ZAREI ET AL.

-5 of 9 neuromuscular junction disorders, neuro-ophthalmological disorders, neurosensory hearing loss and dysautonomia. 49 Most recent reviews give more detailed mechanisms and complications of the Neuro COVID. [49] [50] [51] [52] A retrospective cohort study of 6-month neurological and psy- In a large sample size study in USA, COVID-19 were associated with increased rate of psychiatric disease onset in 14 to 90 days follow-up especially for anxiety disorders, insomnia and dementia. 54 The incidence of first mood anxiety or psychotic disorder in a 6month following a COVID-19 diagnosis was 8.63% followed by anxiety disorder (7.11%), mood disorder (4.22%) and psychotic disorder (0.42%). 29 1. 

Post COVID-19 syndrome signs and symptoms that develop during or after the SARS-CoV-2 infection present for more than 12 weeks

and not attributable to alternative diagnosis. 62 Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations and are the main target population for the intervention of long-term recovery. 63 The clusters of symptoms that persist longest include a combination of neurological/cognitive and systemic symptoms. The reduced work capacity because of cognitive dysfunction, in addition to other debilitating symptoms, translated into the loss of hours, jobs and ability to work relative to pre-illness levels. 64 Sequelae in the respiratory system, as well as several other sequelae that include nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, cardiovascular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain and anaemia. 65 The absolute risk of severe post-acute complications after SARS-CoV-2 infection not requiring hospital admission is low. However, increases in visits to general practitioners and outpatient hospital visits could indicate COVID-19 sequelae. 66 

SARS-CoV-2 has been a pan-systemic disease affecting multi-organ beyond the acute phase of infection and it is yet to be understood.

Approaching to a COVID-19 patient with general considerations, some organs are needed to be closely and immediately assessed when the diagnosis of infection is made, such as kidneys for AKI and cardiac system for myocarditis as well as other systems for later and more persistent effects, such as hormonal imbalances, neuropsychological complications and respiratory insufficiencies. Whilst considering persistent symptoms and effects of the post-COVID-19 syndrome (or as called 'long-COVID') special attention must be paid to patients with underlying co-morbidities. Furthermore, future studies are needed to provide an accurate guideline for approaching this issue as well as a detailed understanding of its pathophysiology.

No funding was received for this study.

A new coronavirus associated with human respiratory disease in China

COVID-19) Dashboard

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission

Post-discharge health status and symptoms in patients with severe COVID-19

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial

Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic

Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms

Swiss recommendations for the follow-up and treatment of pulmonary long COVID

Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City cohort

COVID-19 and cardiovascular disease: from bench to bedside

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers

COVID and cardiovascular disease: what we know in 2021

Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review

Cardiovascular involvement in COVID-19: what sequelae should we expect? Cardiol Ther

Acute kidney injury in a National cohort of hospitalized US Veterans with COVID-19

Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19

High rates of longterm renal recovery in survivors of Coronavirus disease 2019-associated acute kidney injury requiring kidney replacement therapy

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy

Liver function recovery of COVID-19 patients after discharge, a follow-up study

Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age

Effects of SARS-CoV-2 infection on male sex-related hormones in recovering patients

Thyroid function analysis in 50 patients with COVID-19: a retrospective study

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology

Viral nephropathies, adding SARS-CoV-2 to the list

Pathophysiology of COVID-19-associated acute kidney injury

COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients

Initial effects of COVID-19 on patients with ESKD

Cardio-pulmonary-renal consequences of severe COVID-19

Abnormal liver biochemistry tests and acute liver injury in COVID-19 patients: current evidence and potential pathogenesis

Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation

Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: Implications for assessment of post-acute COVID-19 syndrome

Impact of COVID-19 in liver disease progression

Effects of infection with SARS-CoV-2 on the male and female reproductive systems: a review

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

17beta-estradiol reduces SARS-CoV-2 infection in vitro

Evidence for treatment with estradiol for women with SARS-CoV-2 infection

Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh

New-onset diabetes in covid-19

COVID-19 and the endocrine system: a comprehensive review on the theme

Endocrinology in the time of COVID-19: a rapid evolution of knowledge and care

SARS-CoV-2 and nervous system: from pathogenesis to clinical manifestation

SARS-CoV-2 and acute cerebrovascular events: an overview

Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives

Neurological complications of COVID-19

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer

China: a multicentre, retrospective, cohort study

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

Psychological symptoms of cancer survivors during the COVID-19 outbreak: a longitudinal study

High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections

SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis

Mucormycosis -a serious threat in the COVID-19 pandemic?

Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

High-dimensional characterization of postacute sequelae of COVID-19

Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study

Long-term side effects and lingering symptoms post COVID-19 recovery

The authors declare that there is no conflict of interest. 

The data that support the findings of this study are openly available in the cited reference.

https://orcid.org/0000-0002-2239-2055Deepanwita Bose https://orcid.org/0000-0003-4164-6556